Immune Resistance Interrogation Study

Inclusion Criteria:

• Patients with a histological or cytological diagnosis of solid malignancies, with atleast one tumor lesion amenable to core needle biopsy and consent to such aprocedure.

• Patients must have progressed on immunotherapy (defined as anti-PD1/PD-L1 antibodiesgiven as monotherapy or as part of a combination therapy) as their most recent lineof therapy. Patients will be classified into two groups: 1) those who benefittedfrom immunotherapy with either complete response (CR), partial response (PR) orprolonged stable disease (SD) lasting at least 6 months with subsequent progressionor who had disease progression after at least 12 weeks from the last dose ofimmunotherapy in the adjuvant setting (i.e. acquired resistance), 2) those whosedisease is primary refractory to immunotherapy with disease progression at theirfirst on-treatment imaging, those who benefitted from immunotherapy with stabledisease (SD) but progressed in <6 months or those that had progressive diseaseearlier than 12 weeks from the last dose of immunotherapy in the adjuvant setting.

• Patients must be of good performance status, ECOG 0-1, for subsequent anticancertherapy, with either standard treatment or within the context of a clinical trial.

• Patients must be ≥ 18 years old.

• Patients must have provided voluntary written informed consent.

Exclusion Criteria:

• Any condition that could interfere with a patient's ability to provide informedconsent such as dementia or severe cognitive impairment.

• Any contraindication to undergoing venipuncture.

• Any condition that, in the opinion of the Investigator, would interfere with patientsafety, or evaluation of the collected specimens and interpretation of studyresults.